Company Overview and News

 
An evening walk down Dalal Street | A volatile end to the week, Sensex falls 279 pts; DHFL tanks 45%

2018-09-21 moneycontrol
A largely volatile day has come to a close, with indices ending the day on a negative note. However, they are off the day’s low points. The Nifty has managed to give up 11,200 in today’s trade. The Sensex has closed over 200 points lower.
BHRYY 532617 511288 535789 534816 INFRATEL LHFLY 500253 GRAVITA SBAZ GRUH YESBANK KMBKY 511072 533282 IDKQY JETAIRWAYS GRHFY 532648 YYBKY IBULHSGFIN DHFL LICHSGFIN KOTAKBANK 500247

 
Bharti Infratel Limited - Investor Presentation

2018-09-20 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
BHRYY 534816 INFRATEL

 
Vodafone Idea to merge Aditya Birla Telecom

2018-09-17 livemint
New Delhi: Telecom operator Vodafone Idea Limited will merge Aditya Birla Telecom Ltd, which holds 11.15% stake in telecom infrastructure firm Indus Towers, with it.
532454 BHRYY 534816 INFRATEL BHRQY BHARTIARTL

 
Bharti Infratel Limited - Investor Presentation

2018-09-13 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
BHRYY 534816 INFRATEL

3
War for India dominance to spur more billion-dollar tech deals

2018-09-11 livemint
India’s technology industry will see more billion-dollar acquisitions as the next big battleground for foreign Internet companies, according to boutique advisory firm Raine Group LLC.
BRK.A BHRYY 534816 INFRATEL

 
Bharti Infratel touches 52-week low on report of co annually losing Rs 780 crore from Voda-Idea exit

2018-09-06 moneycontrol
Shares of Bharti Infratel touched 52-week low of Rs 266, down nearly 2 percent intraday Thursday as its consolidated revenue to reduce by Rs 780 crore per annum from the merger of Vodafone-Idea.
BHRYY 534816 INFRATEL

 
Bharti Infra to take annual hit of Rs 780 cr from Vodafone Idea exit

2018-09-05 moneycontrol
Telecom infrastructure firm Bharti Infratel said its consolidated revenue, including that from Indus Towers, is expected to take around Rs 780 crore hit on annual basis, due to exit of Vodafone and Idea Cellular from co-located mobile towers.
BHRYY 534816 IDEA ICLQY INFRATEL 532822

 
Bharti Infratel Limited - Updates

2018-09-05 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
BHRYY 534816 INFRATEL

4
An evening walk down Dalal Street | Bulls stage a tough fight, helps market cut losses; Nifty ends above 11,450

2018-09-05 moneycontrol
A good recovery in the last hour helped the market close with shallow cuts. The Sensex managed to recover over 250 points from its low point, while the Nifty shed about 70-odd points from its low points. Both indices closed in the red.
SUNILHITEC YESBANK BHRYY KMBKY 532648 YYBKY 532711 534816 KOTAKBANK INFRATEL 500247 500570 TATAMOTORS TTM

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...